Previous studies and meta-analyses have shown that SGLT2 inhibitors can reduce the risk of incident atrial fibrillation and atrial flutter in patients with T2D and therefore decrease the risk of stroke [17, 22]. This evidence concerns the gene SLC5A2 and atrial flutter.